PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of hsresearchLink to Publisher's site
 
Health Serv Res. 1998 December; 33(5 Pt 1): 1285–1308.
PMCID: PMC1070317

Cost-effectiveness of assertive community treatment versus standard case management for persons with co-occurring severe mental illness and substance use disorders.

Abstract

OBJECTIVE: To determine the cost-effectiveness of Assertive Community Treatment (ACT) in comparison to Standard Case Management (SCM) for persons with severe mental illness and substance use disorders. DATA SOURCES AND STUDY SETTING: Original data on the effectiveness and social costs of ACT and SCM that were collected between 1989 and 1995. Seven community mental health centers in New Hampshire provided both types of treatment. STUDY DESIGN: Persons with schizophrenia, schizoaffective disorder, or bipolar disorder and a concurrent substance use disorder were randomly assigned to ACT or SCM and followed for three years. The primary variables assessed were substance use, psychiatric symptoms, functioning, quality of life, and social costs. DATA COLLECTION METHODS: Effectiveness data were obtained from interviews at six-month intervals with persons enrolled in treatment and with their service providers. Social cost and service utilization data came from client reports; interviews with informal caregivers; provider information systems and Medicaid claims; law enforcement agencies; courts; and community service providers. PRINCIPAL FINDINGS: Participants in both groups showed significant reductions in substance use over time. Focusing on quality of life and substance use outcomes, ACT and SCM were not significantly different in cost-effectiveness over the entire three-year study period. Longitudinal analyses showed that SCM tended to be more efficient during the first two years but that ACT was significantly more efficient than SCM during the final year of the study. CONCLUSIONS: In an adequately funded system, ACT is not more cost-effective than SCM. However, ACT efficiency appears to improve over time.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (2.2M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Abram KM, Teplin LA. Co-occurring disorders among mentally ill jail detainees. Implications for public policy. Am Psychol. 1991 Oct;46(10):1036–1045. [PubMed]
  • Ananth J, Vandewater S, Kamal M, Brodsky A, Gamal R, Miller M. Missed diagnosis of substance abuse in psychiatric patients. Hosp Community Psychiatry. 1989 Mar;40(3):297–299. [PubMed]
  • Atkinson M, Zibin S, Chuang H. Characterizing quality of life among patients with chronic mental illness: a critical examination of the self-report methodology. Am J Psychiatry. 1997 Jan;154(1):99–105. [PubMed]
  • Bartels SJ, Teague GB, Drake RE, Clark RE, Bush PW, Noordsy DL. Substance abuse in schizophrenia: service utilization and costs. J Nerv Ment Dis. 1993 Apr;181(4):227–232. [PubMed]
  • Bartels SJ, Drake RE, McHugo GJ. Alcohol abuse, depression, and suicidal behavior in schizophrenia. Am J Psychiatry. 1992 Mar;149(3):394–395. [PubMed]
  • Bond GR, Miller LD, Krumwied RD, Ward RS. Assertive case management in three CMHCs: a controlled study. Hosp Community Psychiatry. 1988 Apr;39(4):411–418. [PubMed]
  • Bond GR, Witheridge TF, Dincin J, Wasmer D, Webb J, De Graaf-Kaser R. Assertive community treatment for frequent users of psychiatric hospitals in a large city: a controlled study. Am J Community Psychol. 1990 Dec;18(6):865–891. [PubMed]
  • Borland A, McRae J, Lycan C. Outcomes of five years of continuous intensive case management. Hosp Community Psychiatry. 1989 Apr;40(4):369–376. [PubMed]
  • Bush CT, Langford MW, Rosen P, Gott W. Operation outreach: intensive case management for severely psychiatrically disabled adults. Hosp Community Psychiatry. 1990 Jun;41(6):647–651. [PubMed]
  • Carey MP, Carey KB, Meisler AW. Psychiatric symptoms in mentally ill chemical abusers. J Nerv Ment Dis. 1991 Mar;179(3):136–138. [PubMed]
  • Caton CL, Shrout PE, Eagle PF, Opler LA, Felix A, Dominguez B. Risk factors for homelessness among schizophrenic men: a case-control study. Am J Public Health. 1994 Feb;84(2):265–270. [PubMed]
  • Clark RE. Family costs associated with severe mental illness and substance use. Hosp Community Psychiatry. 1994 Aug;45(8):808–813. [PubMed]
  • Clark RE, Drake RE. Expenditures of time and money by families of people with severe mental illness and substance use disorders. Community Ment Health J. 1994 Apr;30(2):145–163. [PubMed]
  • Clark RE, Teague GB, Ricketts SK, Bush PW, Keller AM, Zubkoff M, Drake RE. Measuring resource use in economic evaluations: determining the social costs of mental illness. J Ment Health Adm. 1994 Winter;21(1):32–41. [PubMed]
  • Clark RE, Ricketts SK, McHugo GJ. Measuring hospital use without claims: a comparison of patient and provider reports. Health Serv Res. 1996 Jun;31(2):153–169. [PMC free article] [PubMed]
  • Cuffel BJ, Shumway M, Chouljian TL, MacDonald T. A longitudinal study of substance use and community violence in schizophrenia. J Nerv Ment Dis. 1994 Dec;182(12):704–708. [PubMed]
  • Dickey B, Azeni H. Persons with dual diagnoses of substance abuse and major mental illness: their excess costs of psychiatric care. Am J Public Health. 1996 Jul;86(7):973–977. [PubMed]
  • Dickey B, McGuire TG, Cannon NL, Gudeman JE. Mental health cost models. Refinements and applications. Med Care. 1986 Sep;24(9):857–867. [PubMed]
  • Drake RE, Osher FC, Noordsy DL, Hurlbut SC, Teague GB, Beaudett MS. Diagnosis of alcohol use disorders in schizophrenia. Schizophr Bull. 1990;16(1):57–67. [PubMed]
  • McHugo GJ, Hargreaves W, Drake RE, Clark RE, Xie H, Bond GR, Burns BJ. Methodological issues in assertive community treatment studies. Am J Orthopsychiatry. 1998 Apr;68(2):246–260. [PubMed]
  • Drake RE, Rosenberg SD, Mueser KT. Assessing substance use disorder in persons with severe mental illness. New Dir Ment Health Serv. 1996 Summer;(70):3–17. [PubMed]
  • Gibbons RD, Hedeker D, Waternaux C, Davis JM. Random regression models: a comprehensive approach to the analysis of longitudinal psychiatric data. Psychopharmacol Bull. 1988;24(3):438–443. [PubMed]
  • Gray AM, Marshall M, Lockwood A, Morris J. Problems in conducting economic evaluations alongside clinical trials. Lessons from a study of case management for people with mental disorders. Br J Psychiatry. 1997 Jan;170:47–52. [PubMed]
  • Jerrell JM, Hu TW, Ridgely MS. Cost-effectiveness of substance disorder interventions for people with severe mental illness. J Ment Health Adm. 1994 Summer;21(3):283–297. [PubMed]
  • Kivlahan DR, Heiman JR, Wright RC, Mundt JW, Shupe JA. Treatment cost and rehospitalization rate in schizophrenic outpatients with a history of substance abuse. Hosp Community Psychiatry. 1991 Jun;42(6):609–614. [PubMed]
  • Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982 Dec;38(4):963–974. [PubMed]
  • McHugo GJ, Drake RE, Burton HL, Ackerson TH. A scale for assessing the stage of substance abuse treatment in persons with severe mental illness. J Nerv Ment Dis. 1995 Dec;183(12):762–767. [PubMed]
  • Minkoff K. An integrated treatment model for dual diagnosis of psychosis and addiction. Hosp Community Psychiatry. 1989 Oct;40(10):1031–1036. [PubMed]
  • Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990 Nov 21;264(19):2511–2518. [PubMed]
  • Ridgely MS, Goldman HH, Willenbring M. Barriers to the care of persons with dual diagnoses: organizational and financing issues. Schizophr Bull. 1990;16(1):123–132. [PubMed]
  • Rosenberg SD, Drake RE, Wolford GL, Mueser KT, Oxman TE, Vidaver RM, Carrieri KL, Luckoor R. Dartmouth Assessment of Lifestyle Instrument (DALI): a substance use disorder screen for people with severe mental illness. Am J Psychiatry. 1998 Feb;155(2):232–238. [PubMed]
  • Siegel C, Laska E, Meisner M. Statistical methods for cost-effectiveness analyses. Control Clin Trials. 1996 Oct;17(5):387–406. [PubMed]
  • Teague GB, Drake RE, Ackerson TH. Evaluating use of continuous treatment teams for persons with mental illness and substance abuse. Psychiatr Serv. 1995 Jul;46(7):689–695. [PubMed]
  • Weisbrod BA. A guide to benefit-cost analysis, as seen through a controlled experiment in treating the mentally ill. J Health Polit Policy Law. 1983 Winter;7(4):808–845. [PubMed]
  • Wolff N, Helminiak TW, Diamond RJ. Estimated societal costs of assertive community mental health care. Psychiatr Serv. 1995 Sep;46(9):898–906. [PubMed]

Articles from Health Services Research are provided here courtesy of Health Research & Educational Trust